BR112022026359A2 - Prevenção de dano axonal usando anticorpo que se liga ao beta amiloide 1-42 - Google Patents

Prevenção de dano axonal usando anticorpo que se liga ao beta amiloide 1-42

Info

Publication number
BR112022026359A2
BR112022026359A2 BR112022026359A BR112022026359A BR112022026359A2 BR 112022026359 A2 BR112022026359 A2 BR 112022026359A2 BR 112022026359 A BR112022026359 A BR 112022026359A BR 112022026359 A BR112022026359 A BR 112022026359A BR 112022026359 A2 BR112022026359 A2 BR 112022026359A2
Authority
BR
Brazil
Prior art keywords
prevention
axonal damage
amyloid beta
antibody
binds amyloid
Prior art date
Application number
BR112022026359A
Other languages
English (en)
Inventor
Tan Keith
Shering Craig
R Sims John
L Dage Jeffrey
Original Assignee
Medimmune Ltd
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Lilly Co Eli filed Critical Medimmune Ltd
Publication of BR112022026359A2 publication Critical patent/BR112022026359A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

PREVENÇÃO DE DANO AXONAL USANDO ANTICORPO QUE SE LIGA AO BETA AMILOIDE 1-42. A presente invenção refere-se à prevenção de dano axonal neuronal. Mais particularmente, a presente invenção refere-se à prevenção de dano axonal neuronal usando elementos de ligação que se ligam seletivamente ao peptídeo beta amiloide 1-42 humano (Aß1-42), em que o tratamento de um paciente com o dito elemento de ligação diminui o nível de cadeia leve de neurofilamento (NfL) no paciente.
BR112022026359A 2020-06-25 2021-06-25 Prevenção de dano axonal usando anticorpo que se liga ao beta amiloide 1-42 BR112022026359A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043872P 2020-06-25 2020-06-25
PCT/EP2021/067536 WO2021260193A1 (en) 2020-06-25 2021-06-25 Prevention of axonal damage using antibody binding to amyloid beta 1-42

Publications (1)

Publication Number Publication Date
BR112022026359A2 true BR112022026359A2 (pt) 2023-01-17

Family

ID=76662499

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026359A BR112022026359A2 (pt) 2020-06-25 2021-06-25 Prevenção de dano axonal usando anticorpo que se liga ao beta amiloide 1-42

Country Status (11)

Country Link
US (1) US20230287092A1 (pt)
EP (1) EP4171742A1 (pt)
JP (1) JP2023531069A (pt)
KR (1) KR20230026490A (pt)
CN (1) CN116547299A (pt)
AU (1) AU2021295605A1 (pt)
BR (1) BR112022026359A2 (pt)
CA (1) CA3187785A1 (pt)
IL (1) IL299215A (pt)
TW (1) TW202216188A (pt)
WO (1) WO2021260193A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015951A2 (en) * 2022-07-15 2024-01-18 Seq Biomarque, Llc Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease
CN117624357B (zh) * 2024-01-26 2024-03-22 南京诺唯赞医疗科技有限公司 p-Tau 217特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654A (en) 1848-06-27 Door-spring
US151A (en) 1837-03-25 Spring-saddle
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP0828849B1 (en) 1995-06-02 2006-10-25 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to pdgf
US8481277B2 (en) * 2007-08-21 2013-07-09 Washington University Alzheimer's diagnosis
CN105164156B (zh) 2012-10-15 2019-04-02 米迪缪尼有限公司 针对β淀粉样蛋白的抗体
CN107921109A (zh) 2015-08-19 2018-04-17 阿斯利康(瑞典)有限公司 稳定的抗ifnar1配制品
AU2017232277A1 (en) * 2016-03-15 2018-10-04 Astrazeneca Ab Combination of a BACE inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta

Also Published As

Publication number Publication date
CA3187785A1 (en) 2021-12-30
CN116547299A (zh) 2023-08-04
IL299215A (en) 2023-02-01
US20230287092A1 (en) 2023-09-14
AU2021295605A1 (en) 2023-02-16
WO2021260193A1 (en) 2021-12-30
TW202216188A (zh) 2022-05-01
JP2023531069A (ja) 2023-07-20
KR20230026490A (ko) 2023-02-24
EP4171742A1 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
BR112022026359A2 (pt) Prevenção de dano axonal usando anticorpo que se liga ao beta amiloide 1-42
CO2019010943A2 (es) Anticuerpos de unión a vista a ph ácido
CL2020002410A1 (es) Anticuerpos de unión a vista a ph ácido
BR112022012008A2 (pt) Instrumento cirúrgico compreendendo um mecanismo de fechamento rápido
BR112018000769A2 (pt) anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos
BRPI0921482A8 (pt) Uso de uma construção de anticorpo de cadeia simples biespecífica cd19xcd3 no tratamento de leucemia linfoblástica aguda
ECSP109985A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
BR112012015950A8 (pt) operação de emergência para sinalização de portadora cruzada em operação de multiportadora
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
BR112017021066A2 (pt) glicosídeos de esteviol
BR112016001744A2 (pt) composição polimerizável para material ótico fotocrômico
BR112015032480A2 (pt) método para a produção de um corpo de múltiplas camadas, e corpo de múltiplas camadas
CL2023002543A1 (es) Anticuerpos de unión a vista a ph ácido
BRPI0817684B8 (pt) melhoramentos em elementos de segurança
BR112021020999A2 (pt) Polipeptídeos de ligação à clec12a e usos dos mesmos
BR112018067575A2 (pt) elemento de suporte para o corpo humano, como uma sela
BR112017020148A2 (pt) dispositivo e método de computação óptica
BR112015032339A8 (pt) Composição resistente à água
BR112014018850A8 (pt) Composição e sua utilização no tratamento de rágades anais
CL2022001130A1 (es) Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas
CL2022000627A1 (es) Anticuerpos de unión a vista a ph ácido
BR112019007096A2 (pt) método para a detecção de apolipoproteína e4
BR112019000902A2 (pt) derivado de oxazina para uso na prevenção da doença de alzheimer em pacientes em risco
BR102019000727A8 (pt) Apoio de braço de assento de avião, e, método para expandir um apoio de braço para aeronaves